SCHEMBL22346302

SCHEMBL22346302

C[C@@H](Nc1ccccn1)C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
PKM P14618 2/20 0.50
POLB P06746 1/20 0.50
LMNA P02545 2/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
PIM1 P11309 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44
ADORA1 P30542 1/20 0.44
FLT3 P36888 1/20 0.44
PIM3 Q86V86 1/20 0.44
AURKB Q96GD4 1/20 0.44
FFAR2 O15552 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22346303 1.00 FDPS (0.51) FDPSNPC1RAB9APKMPOLB
Hydrochloric Acid SCHEMBL22346291 0.98 FDPS (0.50) FDPSNPC1RAB9APKMPOLB
Hydrochloric Acid SCHEMBL22346290 0.98 FDPS (0.50) FDPSNPC1RAB9APKMPOLB
SCHEMBL17700271 0.85 FDPS (0.50) FDPSNPC1RAB9APKMPOLB
SCHEMBL44233 0.84 POLB (0.55) FDPSNPC1RAB9APKMPOLB
SCHEMBL6811033 0.84 POLB (0.55) FDPSNPC1RAB9APKMPOLB
SCHEMBL503092 0.84 POLB (0.55) FDPSNPC1RAB9APKMPOLB
SCHEMBL44234 0.84 POLB (0.55) FDPSNPC1RAB9APKMPOLB
SCHEMBL13127918 0.84 FDPS (0.53) FDPSNPC1RAB9APKMPOLB
Hydrochloric Acid SCHEMBL3819373 0.83 FDPS (0.49) FDPSNPC1RAB9APKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4398987-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC Therapeutics, Inc. (US) 2024-07-17 EP claimed
WO-2023039369-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. (US) 2023-03-16 WO claimed
EP-3924049-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC Therapeutics, Inc. (US) 2021-12-22 EP claimed
WO-2020167628-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2020-08-20 WO claimed
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
US-20240390338-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. 2024-11-28 US disclosed
US-20240051968-A1 METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC THERAPEUTICS, INC. (US) 2024-02-15 US disclosed
US-20220135586-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2022-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135586-A1 THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SF3B5, SF3B2, SF3B1 FDPS 569/4885NPC1 2244/4885RAB9A 2133/4885
US-20240051968-A1 METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 ATXN2, ATXN10, ATXN2L FDPS 1673/4885NPC1 870/4885RAB9A 915/4885
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia SF3B5, SF3B2, SF3B1 FDPS 569/4885NPC1 2244/4885RAB9A 2133/4885
US-20240390338-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES MAPT, MAP1B, MAP2 FDPS 1709/4885NPC1 79/4885RAB9A 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.